These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2911846)

  • 1. Interference of spironolactone metabolites in a digoxin radioimmunoassay.
    Crothers DC
    Ther Drug Monit; 1989; 11(1):113-4. PubMed ID: 2911846
    [No Abstract]   [Full Text] [Related]  

  • 2. Spironolactone interference with digoxin radioimmunoassay in cirrhotic patients.
    DiPiro JT; Cote JR; DiPiro CR; Bustrack JA
    Am J Hosp Pharm; 1980 Nov; 37(11):1518-21. PubMed ID: 7211855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone-associated digoxin radioimmunoassay interference.
    Silber B; Sheiner LB; Powers JL; Winter ME; Sadée W
    Clin Chem; 1979 Jan; 25(1):48-50. PubMed ID: 761378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone as a source of interference in commercial digoxin immunoassays.
    Morris RG; Lagnado PY; Lehmann DR; Frewin DB; Glistak ML; Burnet RB
    Ther Drug Monit; 1987 Jun; 9(2):208-11. PubMed ID: 3617160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of spironolactone and digoxin: a review and evaluation.
    Thomas RW; Maddox RR
    Ther Drug Monit; 1981; 3(2):117-20. PubMed ID: 7022769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
    Lichey J; Schröder R; Rietbrock N
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):557-9. PubMed ID: 598949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negligible interference by spironolactone and prednisone in digoxin radioimmunoassay.
    Ravel R
    Clin Chem; 1975 Nov; 21(12):1801-3. PubMed ID: 1183001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W; Müller C; Eber B
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross reactivity of digitoxin and spironolactone in two radioimmunoassays for serum digoxin.
    Müller H; Bräuer H; Resch B
    Clin Chem; 1978 Apr; 24(4):706-9. PubMed ID: 639280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some factors affecting a commercial kit for radioimmunoassay of digoxin using tritiated digoxin.
    Boink AB; Kruyswijk HH; Willebrands AF; Maas AH
    J Clin Chem Clin Biochem; 1977 May; 15(5):261-6. PubMed ID: 894193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
    Pleasants RA; Williams DM; Porter RS; Gadsden RH
    Ther Drug Monit; 1989; 11(2):200-4. PubMed ID: 2655203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of spironolactone and canrenone on the digoxin radioimmunoassay.
    Huffman DH
    Res Commun Chem Pathol Pharmacol; 1974 Dec; 9(4):787-90. PubMed ID: 4477402
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma digoxin radioimmunoassay in patients treated with potassium canrenoate and spironolactone. A comparison of two commerical kits.
    Cristodorescu R; Gavrilescu S; Deutsch G; Berger E
    Agressologie; 1978; 19(6):409-14. PubMed ID: 751526
    [No Abstract]   [Full Text] [Related]  

  • 15. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasma-digoxin concentration in patients at time of hospital admission (author's transl)].
    Lichey J; Schröder R; Rietbrock N
    Dtsch Med Wochenschr; 1977 Jul; 102(29):1056-60. PubMed ID: 891379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An increase in plasma digoxin levels after discontinuation of therapy].
    Duraković Z; Plavsić F; Kuzmanić D
    Lijec Vjesn; 1991; 113(3-4):79-80. PubMed ID: 1890921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of digoxin by radioimmunoassay.
    Walsh PR; Crawford JF; Hawker CD
    Ann Clin Lab Sci; 1977; 7(1):79-87. PubMed ID: 836005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the plasma levels and basic pharmacokinetic parameters of digoxin used in combination with gentamicin, amiodarone and spironolactone.
    Krusteva E
    Folia Med (Plovdiv); 1992; 34(2):24-8. PubMed ID: 1339769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.